The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000433303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
7/07/2025
Date registered
Help: Date registered
9/04/2026
Date last updated
Help: Date last updated
9/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/04/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
SAPLING: Observational study of Severe Acute Pancreatitis Looking into ImmuNe siGnatures
Scientific title
SAPLING: Observational study of Severe Acute Pancreatitis Looking into ImmuNe siGnatures
Additional trial identifiers [1] 314839 0
None
Universal Trial Number (UTN)
Trial acronym
SAPLING: Severe Acute Pancreatitis Looking into ImmuNe siGnatures
Related trial records

Health condition
Health condition(s) studied:
Pancreatitis 338106 0
Condition category
Condition code
Inflammatory and Immune System 334404 334404 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 335278 335278 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Cancer 335279 335279 0 0
Pancreatic

Intervention/exposure
Study type
Observational
Patient registry
False
Target follow-up duration
Target follow-up type
Description of the intervention or exposure
This study will use a convenience sampling strategy. We are targeting a sample of 30 patients with Severe Acute Pancreatitis (SAP) admitted to the ICU for both peripheral blood and tissue (if available) analysis. Additionally, we aim to recruit 60 patients hospitalized with non-severe Acute Pancreatitis (AP), for peripheral blood analysis.

Duration of observation for all participants is 28 days post-recruitment date. Severe Acute Pancreatitis: 30 participants. Blood collected at baseline, day 1, 3, 5, 7, 14 and 28.
Acute Pancreatitis: 60. Blood collected at baseline, day 1, 3, 5, 7, 14 and 28.

Intervention code [1] 331444 0
Diagnosis / Prognosis
Description of the comparator or control
There will be four control groups.
Control Group 1: Consists of 30 participants with pancreatic neoplasms undergoing surgical resection. Tissue sample collected only if they undergo surgery.
Control group 2: Consist of 30 critically ill participants without pancreatic pathology admitted to the ICU (eg. Sepsis, burns). Only Baseline blood collected.
Control group 3 will consist of 30 healthy controls for peripheral blood analysis; Only Baseline blood collected.
Control group 4 will include 30 participants in the ward with acute uncomplicated non-pancreatic intra-abdominal pathology (such as uncomplicated appendicitis, diverticulitis or colitis) Only Baseline blood collected.
Control group
Active

Outcomes
Primary outcome [1] 342092 0
Assess the temporal blood immunological profile in patients with Acute Pancreatitis (both mild and severe).
Timepoint [1] 342092 0
days 1, 3, 5, 7, and days 14 and 28 from hospital admission
Secondary outcome [1] 449555 0
Collect and compare composite pathophysiological and severity of illness data.
Timepoint [1] 449555 0
within 24 hours of ICU admission
Secondary outcome [2] 450629 0
Collect and compare composite pathophysiological and severity of illness data
Timepoint [2] 450629 0
SOFA score calculated on the day of admission and on the day of blood collection

Eligibility
Key inclusion criteria
Patients with acute pancreatitis

Patients admitted to hospital aged =/> 18 years old (greater than or equal to 18 years)
A diagnosis of AP requires the presence of at least 2 of the following criteria (based on the Revised 2012 Atlanta Classification and Definitions of Acute Pancreatitis-
Abdominal pain consistent with acute pancreatitis (typically acute onset of a persistent, severe epigastric pain which may radiate to the back)
Biochemical evidence of acute pancreatitis – serum lipase or amylase elevated more than 3 times the upper limit of normal
Characteristic radiological findings of acute pancreatitis
Patients with SAP will be defined as those admitted to the ICU AND with organ failure (as defined by the Modified Marshall Score)
Participant or Person Responsible consent
Patients previously admitted who present with a recurrence of acute pancreatitis (deemed to be a new episode distinct from the previous) will be suitable for inclusion

Control Group 1 (Patients with intra-abdominal malignancy undergoing surgery, including patients with pancreatic cancer)

Tissue control group
Will have some portion of pancreas resected as part of standard treatment (usually as treatment for a tumour)
Age =/> 18 years old (greater than or equal to 18 years)
Participant consent or Person Responsible consent
The pancreatic surgery unit at RNSH has a long history of biobanking both non-neoplastic and neoplastic tissue from patients undergoing surgical resection of pancreatic tumours. Samples from patients who have previously consented for tissue to be biobanked for medical research will be suitable for inclusion.


Control Group 2 (Critically ill patients within the ICU with a generalised inflammatory state (eg. Sepsis, burns) without pancreatic pathology)

For comparison of peripheral blood markers
Age =/> 18 years old (greater than or equal to 18 years)
Participant or Person Responsible consent

Control Group 3 (Healthy volunteers)

For comparison of peripheral blood immunological markers
Age =/> 18 years old (greater than or equal to 18 years)
To be recruited from existing biobank at Kirby Institute


Control Group 4 (Patients with uncomplicated non-pancreatic acute abdominal pathology (diverticulitis, appendicitis, colitis) – all without any evidence of diffuse peritonitis or acute organ failure)

To compare whether patients with uncomplicated acute abdominal pathologies have a different immune endotype to patients with acute pancreatitis
Age =/> 18 years old (greater than or equal to 18 years)
Participant or Person Responsible consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Exclusion criteria
Patients with acute pancreatitis
• Patients on long term immunomodulatory therapy
• Patients with history of chronic pancreatitis
• Patients with history of pancreatic neoplasm
• Patients with suspected sepsis at the time of diagnosis of pancreatitis

Control groups
• For all control groups, participants with a history of current or prior pancreatitis will be excluded from this study
• Participants on long term immunomodulatory therapy will also be excluded
• For control group 4, patients thought to have sepsis secondary to their primary abdominal condition will be excluded due to the confounding effects of sepsis on the immune analysis
o For control group 4, patients with acute biliary pathology (eg cholecystitis, choledocolithiasis or cholangitis) will be excluded from this cohort due to the risk of concomitant sepsis or pancreatitis confounding the immune analysis
o The definition of sepsis will be based on the Sepsis 3 definition, which requires the presence of severe infection with associated acute organ dysfunction. For the purpose of the study, any patient in control group 4 who has a suspected infection AND acute organ failure (eg. Acute kidney injury, delirium, neutropaenia or thrombocytopaenia, hypotension requiring vasopressors – causing a SOFA score of 2 or more), will be excluded from the study.

Study design
Purpose
Screening
Duration
Longitudinal
Selection
Case control
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 28189 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 44401 0
2065 - St Leonards

Funding & Sponsors
Funding source category [1] 319397 0
University
Name [1] 319397 0
University of New South Wales
Country [1] 319397 0
Australia
Primary sponsor type
University
Name
University of New South Wales
Address
Country
Australia
Secondary sponsor category [1] 321884 0
None
Name [1] 321884 0
None
Address [1] 321884 0
Country [1] 321884 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 317971 0
Northern Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 317971 0
Ethics committee country [1] 317971 0
Australia
Date submitted for ethics approval [1] 317971 0
01/03/2022
Approval date [1] 317971 0
22/05/2023
Ethics approval number [1] 317971 0
2021/ETH12238

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 142734 0
Dr Christopher Andersen
Address 142734 0
Intensive Care Department Royal North Shore Hospital Reserve Road St Leonards NSW 2065
Country 142734 0
Australia
Phone 142734 0
+61294632580
Fax 142734 0
Email 142734 0
Contact person for public queries
Name 142735 0
Christopher Andersen
Address 142735 0
Intensive Care Department Royal North Shore Hospital Reserve Road St Leonards NSW 2065
Country 142735 0
Australia
Phone 142735 0
+61294632580
Fax 142735 0
Email 142735 0
Contact person for scientific queries
Name 142736 0
Christopher Andersen
Address 142736 0
Intensive Care Department Royal North Shore Hospital Reserve Road St Leonards NSW 2065
Country 142736 0
Australia
Phone 142736 0
+61294632580
Fax 142736 0
Email 142736 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
What individual participant data might be shared?
• De-identified individual participant data:
• De-identified data may be shared following approval from the study management team

What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Studies testing whether findings can be repeated or confirmed
• Teaching research methods or developing new statistical techniques
When can requests for individual participant data be made (start and end dates)?
From:
01/01/2027
To:
01/01/2032
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: Principal Investigator [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.